2022-09-14
Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
2022-09-14 • Xiao Liu, Shuangshuang Jia, Yuping Chu, Biao Tian, Yaya Gao, Chunyan Zhang, Yanhua Zheng, Weijing Jia, Xiangxiang Liu, Ruifeng Yuan, Na Zhang, Juan...
Chromosome 1q21 aberration is one of the most common cytogenetic abnormalities in multiple myeloma, and is considered an important prognostic factor. The present study analyzed the clinical relevance and prognostic impact of 1q21 gain in 194 patients with newly diagnosed multiple myeloma treated with bortezomib-based regimens. 1q21 gain was detected in 45.9% (89/194) of patients, and those with 1q21 gain had a worse prognosis. Strikingly, our results showed that excluding the effects of other coinciding genetic an…